Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: Hospital-level prescription of thiazolidinediones for diabetes

European Journal of Health Economics

Volumn 11, Issue 3, 2010, Pages 279-290

  Tsai, Yi Wen ^a,b   Wen, Yu Wen ^a   Huang, Weng Foung ^b   Kuo, Ken N ^a   Chen, Pei Fen ^a   Shih, Hsin Wei ^c   Lee, Yue Chune ^b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c Bureau of Medical Affairs   (Taiwan)

Author keywords

Concentration; Diabetes; Herfindahl Hirschman indices; New drug; Penetration

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETOHEXAMIDE; BUFORMIN; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; TOLAZAMIDE; DRUG;

ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; DRUG MARKETING; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; TAIWAN; CLASSIFICATION; CLINICAL PRACTICE; DRUG INDUSTRY; ECONOMIC ASPECT; ECONOMICS; FACTUAL DATABASE; FINANCIAL MANAGEMENT; HOSPITAL; PUBLIC HEALTH; STATISTICS;

DATABASES, FACTUAL; DIABETES MELLITUS; DRUG INDUSTRY; ECONOMIC COMPETITION; HOSPITALS; HUMANS; MARKETING OF HEALTH SERVICES; NATIONAL HEALTH PROGRAMS; PHARMACEUTICAL PREPARATIONS; PHYSICIAN'S PRACTICE PATTERNS; TAIWAN; THIAZOLIDINEDIONES;

EID: 77954479332     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-009-0174-1     Document Type: Article

References (39)

1. Cutler, D.M., McClellan, M., Newhouse, J.P., Remler, D.: Are medical prices declining? Evidence from heart attack treatments. Q. J. Econ. 113, 991 (1998)
2. Dozet, A., Lyttkens, C.H., Nystedt, P.: Health care for the elderly: two cases of technology diffusion. Soc. Sci. Med. 54, 49 (2002)
3. Baker, L.C.: Managed care and technology adoption in health care: evidence from magnetic resonance imaging. J. Health Econ. 20, 395 (2001)
4. Baker, L.C., Phibbs, C.S.: Managed care, technology adoption and health care: the adoption of neonatal intensive care. Rand J. Econ. 33, 524 (2002)
5. Burke, M.A., Fournier, G.M., Prasad, K.: The diffusion of a medical innovation: is success in the stars? South. Econ. J. 73, 588 (2007)
6. Poulsen, P.B., Vondeling, H., Dirksen, C.D., Adamsen, S., Go, P.M.N.Y.H., Ament, A.J.H.: Timing of adoption of laparoscopic cholecystectomy in Denmark and in The Netherlands: a comparative study. Health Policy 55, 85 (2001)
7. Moloney, T.W., Rogers, D.E.: Medical technology-a different view of the contentious debate over costs. N. Engl. J. Med. 301, 1413 (1979)
8. Rudholm, N.: Competition and substitutability in the Swedish pharmaceuticals market. Appl. Econ. 35, 1609 (2003)
9. Bae, J.P.: Drug patent expirations and speed of generic entry. Health Serv. Res. 32, 87 (1997)
10. Berndt, E.R., Bui, L., Reiley, D.R., Urban, G.L.: Information, marketing, and pricing in the US antiulcer drug market. Am. Econ. Rev. 85, 100 (1995)
11. Ellison, S.F., Cockburn, I., Griliches, Z., Hausman, J.: Characteristics of demand for pharmaceutical products: an examination of four cephalosporins. Rand J. Econ. 28, 426 (1997)
12. Grabowski, H.G., Vernon, J.M.: Brand loyalty, entry and price competition in pharmaceuticals after the 1984 Drug Act. J. Law Econ. 35, 331 (1992)
13. Rudholm, N.: Entry and the number of firms in the Swedish pharmaceuticals market. Rev. Ind. Org. 19, 351 (2001)
14. Acemoglu, D., Linn, J.: Market size in innovation: theory and evidence from the pharmaceutical industry. Q. J. Econ. 119, 1049 (2004)
15. Morton, F.M.S.: Entry decisions in the generic pharmaceutical industry. Rand J. Econ. 30, 421 (1999)
16. Aronsson, T., Bergman, M.A., Rudholm, N.: The impact of generic drug competition on brand name market shares-evidence from micro data. Rev. Ind. Org. 19, 423 (2001)
17. Frank, R.G., Salkever, D.S.: Generic entry and the pricing of pharmaceuticals. J. Econ. Manag. Strategy 6, 75 (1997)
18. Hudson, J.: Pricing dynamics in the pharmaceutical industry. Appl. Econ. 24, 103 (1992)
19. Caves, R.E., Whinston, M.D., Hurwitz, M.A.: Patent expiration, entry, and competition in the US pharmaceutical industry. Brookings Pap. Econ. Act. 1991, 1 (1991)
20. Frank, R., Salkever, D.S.: Pricing, patent loss and the market for pharmaceuticals. South. Econ. J. 59, 165 (1992)
21. Frank, R.G.: Prescription drug prices: why do some pay more than others do? Health Aff. 20, 115 (2001)
22. Saha, A., Grabowski, H., Birnbaum, H., Greenberg, P., Bizan, O.: Generic competition in the US pharmaceutical industry. Int. J. Econ. Bus. 13, 15 (2006)
23. Rogers, E.M.: Diffusion of innovations. Simon and Schuster, New York (2003)
24. Hellerstein, J.K.: The importance of the physician in the generic versus trade-name prescription decision. Rand J. Econ. 29, 108 (1998)
25. Pauly, M.V.: Monopsony power in health insurance: thinking straight while standing on your head. J. Health Econ. 6, 73 (1987)
26. Snyder, C.M.: Why do larger buyers pay lower prices? Intense supplier competition. Econ. Lett. 58, 205 (1998)
27. Dusing, M.L., Guo, J.J., Kelton, C.M., Pasquale, M.K.: Competition and price discounts for a hospital buyer in the anti-infective pharmaceutical market. J. Pharm. Finan. Econ. Pol. 14, 59 (2005)
28. Martin, S.: Market power and/or efficiency? Rev. Econ. Stat. 70, 331 (1988)
29. Staten, M., Umbeck, J., Dunkelberg, W.: Market share/market power revisited : a new test for an old theory. J. Health Econ. 7, 73 (1988)
30. Hsieh, C.-R., Sloan, F.A.: Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost effective? Value Health. 11, 334 (2008)
31. BNHI: National Health Insurance Statistics Report. Bureau of National Health Insurance, Taipei (2008)
32. BNHI. National Health Insurance Act. Available at: http://www.nhi.gov.tw/ english. Accessed 5 May 2009
33. BNHI. Drug Formulary of National Health Insurance. 2009. Available at: http://www.nhi.gov.tw/webdata/webdata.asp?menu=3&menu-id=56&webdata-id= 1099&WD-ID=. Accessed 6 May 2009
34. Lee, Y.-C., Yang, M.-C., Huang, Y.-T., Liu, C.-H., Chen, S.-B.: Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996- 2003. Pharmacoeconomics 24, 891 (2006)
35. Diamant, M., Heine, R.J.: Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs. 63, 1373 (2003)
36. Cohen, F.J., Neslusan, C.A., Conklin, J.E., Song, X.: Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care 26, 1847 (2003)
37. Laird, N.M., Ware, J.H.: Random-effects models for longitudinal data. Biometrics 38, 963 (1982)
38. Liang, K.-Y., Zeger, S.L.: Longitudinal data analysis using generalized linear models. Biometrika 73, 13 (1986)
39. Zeger, S.L., Liang, K.-Y.: Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42, 121 (1986)